Overactive Bladder



Overactive bladder (OAB) is an umbrella term that includes the symptoms of urinary urgency, frequency, nocturia, and/or urgency incontinence. Prevalence of this condition is reported to be higher in women and also reported to increase with age, with estimates extending up to 40 % after 70 years [1, 2]. OAB has a significant impact upon quality of life [3], as well as having a significant impact on the healthcare system with annual costs ranging from 66 billion US dollars. These costs are related to the routine costs of pads and diapers to patients, as well as the costs associated with the increased risk for falls and fractures, infections, and physical compromise [1]. Asking patients if they suffer these symptoms and tailoring an appropriate and effective treatment regimen is of great value not only for the patient but also for the healthcare system.


Overactive Bladder Detrusor Overactivity Urgency Incontinence Sacral Nerve Stimulation Incontinence Episode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65:79–95.PubMedCrossRefGoogle Scholar
  2. 2.
    Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32:230–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–63.PubMedCrossRefGoogle Scholar
  4. 4.
    Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM, Redden DT. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. J Urol. 2010;184:598–603.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25:327–38.PubMedCrossRefGoogle Scholar
  8. 8.
    Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2014;5:CD005654.Google Scholar
  9. 9.
    Subak LL, Johnson C, Whitcomb E, Boban D, Saxton J, Brown JS. Does weight loss improve incontinence in moderately obese women? Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:40–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360:481–90.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(861–74):W301–10.Google Scholar
  12. 12.
    Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3 % in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2014. doi:  10.1002/nau.22504.
  19. 19.
    Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62:1040–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.PubMedCrossRefGoogle Scholar
  21. 21.
    Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63:283–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center randomized double-blind placebo controlled trial. J Urol. 2007;177:2231–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Visco AG, Brubaker L, Richter HE, et al. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. Contemp Clin Trials. 2012;33:184–96.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinum toxin A for idiopathic overactive bladder: a double-blind placebo controlled randomized dose ranging trial. J Urol. 2010;184:2416–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Nitti VW, Dmochowski R, Herschorn S, et al. Onabotulinum toxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Chapple C, Sievert KD, MacDiarmid S, et al. Onabotulinum toxin A 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181:2608–15.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180:217–22.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Zyczynski H for the PFDN. Comparison of cost-effectiveness of onabotulinum toxin A and anticholinergic medications for the treatment of urgency urinary incontinence. Female Pelvic Med Reconstr Surg. 2013;19(5 Suppl):S45–S190.Google Scholar
  33. 33.
    Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982;20:614–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.PubMedCrossRefGoogle Scholar
  35. 35.
    van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Siddiqui NY, Wu JM, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29 Suppl 1:S18–23.PubMedCrossRefGoogle Scholar
  37. 37.
    White WM, Mobley 3rd JD, Doggweiler R, Dobmeyer-Dittrich C, Klein FA. Incidence and predictors of complications with sacral neuromodulation. Urology. 2009;73:731–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. 2010;14:1081–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Spinelli M, Sievert KD. Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol. 2008;54:1287–96.PubMedCrossRefGoogle Scholar
  40. 40.
    Blandon RE, Gebhart JB, Lightner DJ, Klingele CJ. Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women. BJU Int. 2008;101:1119–23.PubMedCrossRefGoogle Scholar
  41. 41.
    Washington BB, Hines BJ. Implant infection after two-stage sacral nerve stimulator placement. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1477–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Amend B, Matzel KE, Abrams P, de Groat WC, Sievert KD. How does neuromodulation work? Neurourol Urodyn. 2011;30:762–5.PubMedCrossRefGoogle Scholar
  43. 43.
    de Groat WC, Kawatani M. Reorganization of sympathetic preganglionic connections in cat bladder ganglia following parasympathetic denervation. J Physiol. 1989;409:431–49.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;56:87–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.PubMedCrossRefGoogle Scholar
  46. 46.
    Mellgren A, Wexner SD, Coller JA, et al. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence. Dis Colon Rectum. 2011;54:1065–75.PubMedCrossRefGoogle Scholar
  47. 47.
    Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–45.PubMedCrossRefGoogle Scholar
  48. 48.
    Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014. doi:  10.1002/nau.22544
  49. 49.
    Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43.PubMedCrossRefGoogle Scholar
  50. 50.
    MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183:234–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyUC Riverside School of Medicine, University of CaliforniaOaklandUSA

Personalised recommendations